2021 Infectious Disease Testing: US, Europe, Japan-A Rapidly Growing and Challenging Market-Supplier Shares and Segment Forecasts for 100 Tests-Technological Breakthroughs, Emerging Tests, Competitive Analysis
LeadingMarketResearch.com's new report is a seven-country strategic analysis of major business opportunities emerging in the infectious disease testing market during the next five years.
The report is available by section, and can be customized to specific information needs and budget.
The report examines key trends in the U.S., five major European countries (France, Germany, Italy, Japan, UK) and Japan; reviews current and emerging assays; analyzes potential applications of innovative diagnostic technologies; forecasts volume and sales for over 100 infectious disease tests by assay, market segment, and country; provides test volume estimates by method (molecular, serology/immunodiagnostics, culture/microscopy); profiles leading players and potential market entrants; and suggests alternative business expansion strategies for suppliers.
Rationale
This comprehensive seven-country report will assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding microbiology testing market, in evaluating emerging opportunities and developing effective business strategies.
Microbiology testing is one of the most rapidly growing segments of the in vitro diagnostics industry, and the greatest challenge facing suppliers during this decade. Among the main driving forces is continuing spread of AIDS, which remains the world's major health threat and a key factor contributing to the rise of opportunistic infections; threat of bioterrorism; advances in molecular diagnostic technologies; and a wider availability of immunosuppressive drugs.
Although for some infections the etiology is still a mystery, while for others the causative microorganisms are present in minute concentrations long before the occurrence of first clinical symptoms, recent advances in genetic engineering and detection technologies are creating exciting opportunities for highly sensitive, specific and cost-effective products.
Worldwide Market Overview
AIDS/HIV, Adenovirus, Aeromonads, Bartonella, Blastocystis Hominis, Campylobacter, Candida, Chancroid, Chlamydia, Clostridium, Coronavirus, Coxsackievirus, Cryptosporidium, Cyclospora, CMV, E. Coli, Echovirus, Encephalitis, Enterovirus, EBV, Giardia, Gonorrhea, Granuloma Inguinale, Hantavirus, H. Pylori, Hepatitis, Herpes Influenza, Legionella, Lyme disease, Lymphogranuloma, Malaria, Measles, Meningitis, Microsporidium, Mononucleosis, Mumps, Mycoplasma, HPV, Parvovirus, Pneumonia, Polyomaviruses, Pseudomonas, Rabies, RSV, Rhinovirus, Rotavirus , Rubella, Salmonella, Septicemia, Shigella, Staphylococci, Streptococci, Syphilis, Toxoplasmosis, Trichomonas, TB, Vibrio, West Nile, Yersinia.
Geographic Coverage
Strategic assessments of major suppliers and emerging market entrants, including their sales, product portfolios, marketing tactics, collaborative arrangements and new products in R&D.
Contains 1,900 pages and 317 tables
The report is available by section, and can be customized to specific information needs and budget.
The report examines key trends in the U.S., five major European countries (France, Germany, Italy, Japan, UK) and Japan; reviews current and emerging assays; analyzes potential applications of innovative diagnostic technologies; forecasts volume and sales for over 100 infectious disease tests by assay, market segment, and country; provides test volume estimates by method (molecular, serology/immunodiagnostics, culture/microscopy); profiles leading players and potential market entrants; and suggests alternative business expansion strategies for suppliers.
Rationale
This comprehensive seven-country report will assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding microbiology testing market, in evaluating emerging opportunities and developing effective business strategies.
Microbiology testing is one of the most rapidly growing segments of the in vitro diagnostics industry, and the greatest challenge facing suppliers during this decade. Among the main driving forces is continuing spread of AIDS, which remains the world's major health threat and a key factor contributing to the rise of opportunistic infections; threat of bioterrorism; advances in molecular diagnostic technologies; and a wider availability of immunosuppressive drugs.
Although for some infections the etiology is still a mystery, while for others the causative microorganisms are present in minute concentrations long before the occurrence of first clinical symptoms, recent advances in genetic engineering and detection technologies are creating exciting opportunities for highly sensitive, specific and cost-effective products.
Worldwide Market Overview
- Estimated universe of laboratories performing infectious disease testing by country.
- Test volume and sales projections for major infectious disease diagnostic assays by country.
- Emerging opportunities for new instrumentation, reagents kits, IT and other products with significant market appeal during the next five years.
- Design criteria for decentralized testing products.
- Alternative market penetration strategies.
- Potential market entry barriers and risks.
AIDS/HIV, Adenovirus, Aeromonads, Bartonella, Blastocystis Hominis, Campylobacter, Candida, Chancroid, Chlamydia, Clostridium, Coronavirus, Coxsackievirus, Cryptosporidium, Cyclospora, CMV, E. Coli, Echovirus, Encephalitis, Enterovirus, EBV, Giardia, Gonorrhea, Granuloma Inguinale, Hantavirus, H. Pylori, Hepatitis, Herpes Influenza, Legionella, Lyme disease, Lymphogranuloma, Malaria, Measles, Meningitis, Microsporidium, Mononucleosis, Mumps, Mycoplasma, HPV, Parvovirus, Pneumonia, Polyomaviruses, Pseudomonas, Rabies, RSV, Rhinovirus, Rotavirus , Rubella, Salmonella, Septicemia, Shigella, Staphylococci, Streptococci, Syphilis, Toxoplasmosis, Trichomonas, TB, Vibrio, West Nile, Yersinia.
Geographic Coverage
- France
- Germany
- Italy
- Japan
- Spain
- UK
- US
- Sales and market shares of major suppliers by individual test and country.
- Volume and sales forecasts for over 100 infectious disease assays by country, individual test and market segment:
- Hospitals
- Blood Banks
- Commercial/Private Laboratories
- Physician Offices/Group Practices
- Public Health Laboratories
- Test volume estimates by method (molecular, serology/immunodiagnostics, culture/microscopy).
- Review of the market dynamics, trends, structure, size, growth and major suppliers by country.
- In-depth examination of over 100 major diseases, including their etiology, current diagnostic tests, vaccines, drugs and market needs.
- Review of major analyzers used for infectious disease testing, including their operating characteristics, features and selling prices.
- Assessment of molecular diagnostic, monoclonal antibody, immunoassay, and other technologies and their potential applications for infectious disease testing.
- Global listings of companies developing or marketing infectious disease diagnostic products by individual test.
Strategic assessments of major suppliers and emerging market entrants, including their sales, product portfolios, marketing tactics, collaborative arrangements and new products in R&D.
Contains 1,900 pages and 317 tables
I. INTRODUCTION
II. WORLDWIDE MARKET OVERVIEW
A. Business Environment
B. Market Structure
C. Market Size and Growth
III. MAJOR PRODUCT DEVELOPMENT OPPORTUNITIES
A. Instrumentation
B. Reagent Kits and Test Systems/panels
C. Information Technology
D. Auxiliary Products
IV. DESIGN CRITERIA FOR DECENTRALIZED TESTING PRODUCTS
V. ALTERNATIVE MARKET PENETRATION STRATEGIES
A. Internal Development
B. Collaborative Arrangements
C. University Contracts
D. Distribution Strategies for Decentralized Testing Markets
1. Marketing Approaches
2. Product Complexity
3. Customer Preference
4. Established Suppliers
5. Emerging Suppliers
6. Major Types of Distributors
7. Market Segmentation
VI. POTENTIAL MARKET ENTRY BARRIERS AND RISKS
A. Market Maturity
B. Cost Containment
C. Competition
D. Technological Edge and Limitations
E. Patent Protection
F. Regulatory Constraints
G. Decentralized Testing Market Challenges
VII. WORLDWIDE OVERVIEW OF MAJOR TESTS, TECHNOLOGIES, AND INSTRUMENTATION
A. Major Infectious Disease Tests
1. AIDS
2. Adenovirus
3. Aeromonas
4. Anthrax/Bacillus Anthracis
5. Arboviruses
6. Babesiosis
7. Bacillary Epithelioid Angiomatosis (BEA) and Other Bartonella (Rochalimaea)
8. Blastocystis Hominis
9. Brucella
10. Campylobacter
11. Candida
12. Chagas Disease
13. Chancroid
14. Chlamydia
15. Clostridium Difficile
16. Coronaviruses
17. Coxsackieviruses
18. Creutzfeldt-Jakob’s Disease
19. Cryptosporidium Parvum
20. Cyclospora Cayetanensis
21. Cytomegalovirus
22. Ebola Virus
23. E. Coli
24. EchoVirus
25. Encephalitis
26. Enteroviruses
27. Epstein-Barr Virus
28. Giardia Lamblia
29. Gonorrhea
30. Granuloma Inguinale
31. Hantavirus
32. Helicobacter Pylori
33. Hepatitis
34. Herpes Simplex Virus
35. Human Herpes Virus-6 (HHV-6)
36. Influenza Viruses
37. Legionella
38. Lyme Disease
39. Lymphogranuloma Venereum (LGV)
40. Malaria
41. Measles (Rubeola)
42. Meningitis
43. Microsporidium
44. Mononucleosis
45. Mumps
46. Mycoplasma
47. Papillomaviruses
48. Parvovirus B19
49. Pneumonia
50. Polyomaviruses
51. Pseudomonas Aeruginosa
52. Rabies
53. Respiratory Syncytial Virus (RSV)
54. RhinoViruses
55. RotaVirus (REOVIRUS)
56. Rubella(MEASLES)
57. Salmonellosis
58. Septicemia
59. Shigellosis
60. Staphylococcus Aureus
61. Streptococci
62. Syphilis
63. Toxoplasmosis
64. Trichomonas Vaginalis
65. Tuberculosis
66. Vibrio
67. West Nile Virus
68. Yersina
B. Instrumentation Review: Operating Characteristics, Features and Selling Princes of Leading Automated and Semiautomated Analyzers
C. Emerging Diagnostic Technologies
1. Molecular Diagnostics
2. Monoclonal Antibodies
3. Immunoassays
4. Differential Light Scattering
5. Information Technology
6. Artificial Intelligence
7. Liposomes
8. Flow Cytometry
9. Chromatography
10. Diagnostic Imaging
11. Gel Microdroplets
12. Other
D. Personal Testing
VIII. FRANCE
A. Executive Summary
B. Business Environment
C. Market Structure
D. Market Size, Growth, Volume by Method, and Major Suppliers’ Sales and Market Shares by Test
IX. GERMANY
A. Executive Summary
B. Business Environment
C. Market Structure
D. Market Size, Growth, Volume by Method, and Major Suppliers’ Sales and Market Shares by Test
X. ITALY
A. Executive Summary
B. Business Environment
C. Market Structure
D. Market Size, Growth Volume by Method, and Major Suppliers’ Sales and Market Shares by Test
XI. JAPAN
A. Executive Summary
B. Business Environment
C. Market Structure
D. Market Size, Growth, Volume by Method, and Major Suppliers’ Sales and Market Shares by Test
XII. SPAIN
A. Executive Summary
B. Business Environment
C. Market Structure
D. Market Size, Growth, Volume by Method, and Major Suppliers’ Sales and Market Shares by Test
XIII. U.K.
A. Executive Summary
B. Business Environment
C. Market Structure
D. Market Size, Growth, Volume by Method, and Major Suppliers’ Sales and Market Shares by Test
XIV. U.S.A.
A. Executive Summary
B. Business Environment
C. Market Structure
D. Market Size, Growth, Volume by Method, and Major Suppliers’ Sales and Market Shares by Test
XV. COMPETITIVE ASSESSMENTS
Abbott
Affymetrix
Beckman Coulter/Danaher
Becton Dickinson
bioMerieux
Bio-Rad
Cepheid
Diamedix
DiaSorin
Eiken Chemical
Elitech Group
Enzo Biochem
Fujirebio
Grifols
GSK Biologicals
Hologic
Leica Biosystems
Lonza
Ortho-Clinical Diagnostics
PerkinElmer
Qiagen
Roche
Scienion
Sequenom
SeraCare
Siemens Healthineers
Takara Bio
Thermo Fisher
Wako
XVI. APPENDIX: ASSUMED CURRENCY EXCHANGE RATES
II. WORLDWIDE MARKET OVERVIEW
A. Business Environment
B. Market Structure
C. Market Size and Growth
III. MAJOR PRODUCT DEVELOPMENT OPPORTUNITIES
A. Instrumentation
B. Reagent Kits and Test Systems/panels
C. Information Technology
D. Auxiliary Products
IV. DESIGN CRITERIA FOR DECENTRALIZED TESTING PRODUCTS
V. ALTERNATIVE MARKET PENETRATION STRATEGIES
A. Internal Development
B. Collaborative Arrangements
C. University Contracts
D. Distribution Strategies for Decentralized Testing Markets
1. Marketing Approaches
2. Product Complexity
3. Customer Preference
4. Established Suppliers
5. Emerging Suppliers
6. Major Types of Distributors
7. Market Segmentation
VI. POTENTIAL MARKET ENTRY BARRIERS AND RISKS
A. Market Maturity
B. Cost Containment
C. Competition
D. Technological Edge and Limitations
E. Patent Protection
F. Regulatory Constraints
G. Decentralized Testing Market Challenges
VII. WORLDWIDE OVERVIEW OF MAJOR TESTS, TECHNOLOGIES, AND INSTRUMENTATION
A. Major Infectious Disease Tests
1. AIDS
2. Adenovirus
3. Aeromonas
4. Anthrax/Bacillus Anthracis
5. Arboviruses
6. Babesiosis
7. Bacillary Epithelioid Angiomatosis (BEA) and Other Bartonella (Rochalimaea)
8. Blastocystis Hominis
9. Brucella
10. Campylobacter
11. Candida
12. Chagas Disease
13. Chancroid
14. Chlamydia
15. Clostridium Difficile
16. Coronaviruses
17. Coxsackieviruses
18. Creutzfeldt-Jakob’s Disease
19. Cryptosporidium Parvum
20. Cyclospora Cayetanensis
21. Cytomegalovirus
22. Ebola Virus
23. E. Coli
24. EchoVirus
25. Encephalitis
26. Enteroviruses
27. Epstein-Barr Virus
28. Giardia Lamblia
29. Gonorrhea
30. Granuloma Inguinale
31. Hantavirus
32. Helicobacter Pylori
33. Hepatitis
34. Herpes Simplex Virus
35. Human Herpes Virus-6 (HHV-6)
36. Influenza Viruses
37. Legionella
38. Lyme Disease
39. Lymphogranuloma Venereum (LGV)
40. Malaria
41. Measles (Rubeola)
42. Meningitis
43. Microsporidium
44. Mononucleosis
45. Mumps
46. Mycoplasma
47. Papillomaviruses
48. Parvovirus B19
49. Pneumonia
50. Polyomaviruses
51. Pseudomonas Aeruginosa
52. Rabies
53. Respiratory Syncytial Virus (RSV)
54. RhinoViruses
55. RotaVirus (REOVIRUS)
56. Rubella(MEASLES)
57. Salmonellosis
58. Septicemia
59. Shigellosis
60. Staphylococcus Aureus
61. Streptococci
62. Syphilis
63. Toxoplasmosis
64. Trichomonas Vaginalis
65. Tuberculosis
66. Vibrio
67. West Nile Virus
68. Yersina
B. Instrumentation Review: Operating Characteristics, Features and Selling Princes of Leading Automated and Semiautomated Analyzers
C. Emerging Diagnostic Technologies
1. Molecular Diagnostics
2. Monoclonal Antibodies
3. Immunoassays
4. Differential Light Scattering
5. Information Technology
6. Artificial Intelligence
7. Liposomes
8. Flow Cytometry
9. Chromatography
10. Diagnostic Imaging
11. Gel Microdroplets
12. Other
D. Personal Testing
VIII. FRANCE
A. Executive Summary
B. Business Environment
C. Market Structure
D. Market Size, Growth, Volume by Method, and Major Suppliers’ Sales and Market Shares by Test
IX. GERMANY
A. Executive Summary
B. Business Environment
C. Market Structure
D. Market Size, Growth, Volume by Method, and Major Suppliers’ Sales and Market Shares by Test
X. ITALY
A. Executive Summary
B. Business Environment
C. Market Structure
D. Market Size, Growth Volume by Method, and Major Suppliers’ Sales and Market Shares by Test
XI. JAPAN
A. Executive Summary
B. Business Environment
C. Market Structure
D. Market Size, Growth, Volume by Method, and Major Suppliers’ Sales and Market Shares by Test
XII. SPAIN
A. Executive Summary
B. Business Environment
C. Market Structure
D. Market Size, Growth, Volume by Method, and Major Suppliers’ Sales and Market Shares by Test
XIII. U.K.
A. Executive Summary
B. Business Environment
C. Market Structure
D. Market Size, Growth, Volume by Method, and Major Suppliers’ Sales and Market Shares by Test
XIV. U.S.A.
A. Executive Summary
B. Business Environment
C. Market Structure
D. Market Size, Growth, Volume by Method, and Major Suppliers’ Sales and Market Shares by Test
XV. COMPETITIVE ASSESSMENTS
Abbott
Affymetrix
Beckman Coulter/Danaher
Becton Dickinson
bioMerieux
Bio-Rad
Cepheid
Diamedix
DiaSorin
Eiken Chemical
Elitech Group
Enzo Biochem
Fujirebio
Grifols
GSK Biologicals
Hologic
Leica Biosystems
Lonza
Ortho-Clinical Diagnostics
PerkinElmer
Qiagen
Roche
Scienion
Sequenom
SeraCare
Siemens Healthineers
Takara Bio
Thermo Fisher
Wako
XVI. APPENDIX: ASSUMED CURRENCY EXCHANGE RATES
